Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152161 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL14889921 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL29670877 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL14890072 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL8836139 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL14890074 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL155228 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL14889920 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL8836145 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL25869247 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4495237-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2026-05-13 | — | — | EP | disclosed |
| EP-4036079-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-3275448-B1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES | KYOWA KIRIN CO LTD (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-12453776-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2025-10-28 | — | — | US | disclosed |
| EP-3456317-B1 | DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS | ALNYLAM PHARMACEUTICALS INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3394030-B2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4495237-A2 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2025-01-22 | — | — | EP | disclosed |
| US-20240424105-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-12-26 | — | — | US | disclosed |
| EP-4241767-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2024-10-23 | — | — | EP | disclosed |
| WO-2009132131-A1 | AMINO LIPID BASED IMPROVED LIPID FORMULATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129387-A2 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129395-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| US-7514099-B2 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090048197-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | SIRNA THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080188675-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | SIRNA THERAPEUTICS INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-7404969-B2 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080020058-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20060240554-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048197-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | PHAX, CETP, LIPC | FAAH 1505/4885KDM4E 3974/4885USP2 4413/4885 |
| US-12453776-B2 | Lipids and compositions for the delivery of therapeutics | PHOSPHO1, MBOAT1, SGMS1 | FAAH 550/4885KDM4E 1867/4885USP2 3230/4885 |
| US-20060240554-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | PHAX, CETP, LIPC | FAAH 1624/4885KDM4E 3996/4885USP2 4357/4885 |
| US-20240424105-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | PHOSPHO1, MBOAT1, SGMS1 | FAAH 503/4885KDM4E 1963/4885USP2 3127/4885 |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | FAAH 3097/4885KDM4E 4340/4885USP2 1288/4885 |
| US-20080020058-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | PHAX, CETP, LIPC | FAAH 1505/4885KDM4E 3974/4885USP2 4413/4885 |
| US-20080188675-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | PHAX, CETP, LIPC | FAAH 1624/4885KDM4E 3996/4885USP2 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.